support@mellalta.com   +1 (304) 306-0723

Familial chylomicronemia syndrome (FCS)- Refile NDA for Volanesorsen (WAYLIVRA) with USFDA in H2 2020

Volanesorsen-WAYLIVRA-Familial-chylomicronemia-syndrome-FCS-in-H2-2020

Volanesorsen (WAYLIVRA) is the leading drug in Familial chylomicronemia syndrome (FCS) space globally., developed by Ionis & Akcea Therapeutics. Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disease caused by mutations in the lipoprotein […]

Read More

Get In Touch

Let's keep the conversation going